Pharmacogenomics to Revive Drug Development in Cardiovascular Disease

Cardiovascular Drugs and Therapy
Marie-Pierre DubéJean-Claude Tardif

Abstract

Investment in cardiovascular drug development is on the decline as large cardiovascular outcomes trials require considerable investments in time, efforts and financial resources. Pharmacogenomics has the potential to help revive the cardiovascular drug development pipeline by providing new and better drug targets at an earlier stage and by enabling more efficient outcomes trials. This article will review some of the recent developments highlighting the value of pharmacogenomics for drug development. We discuss how genetic biomarkers can enable the conduct of more efficient clinical outcomes trials by enriching patient populations for good responders to the medication. In addition, we assess past drug development programs which support the added value of selecting drug targets that have established genetic evidence supporting the targeted mechanism of disease. Finally, we discuss how pharmacogenomics can provide valuable evidence linking a drug target to clinically relevant outcomes, enabling novel drug discovery and drug repositioning opportunities.

References

Aug 10, 1989·The New England Journal of Medicine·UNKNOWN Cardiac Arrhythmia Suppression Trial (CAST) Investigators
Oct 1, 1996·Annals of Internal Medicine·T R Fleming, D L DeMets
Oct 27, 1997·The New England Journal of Medicine·UNKNOWN Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO III) Investigators
May 6, 2003·Nature Genetics·Marianne AbifadelCatherine Boileau
Apr 13, 2004·International Journal of Epidemiology·Duncan C Thomas, David V Conti
Feb 17, 2005·The New England Journal of Medicine·Robert S BresalierUNKNOWN Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators
Mar 24, 2006·The New England Journal of Medicine·Jonathan C CohenHelen H Hobbs
Aug 24, 2007·Statistical Methods in Medical Research·Vanessa Didelez, Nuala Sheehan
Nov 7, 2007·The New England Journal of Medicine·Philip J BarterUNKNOWN ILLUMINATE Investigators
Jul 9, 2008·Annals of Medicine·George Davey SmithShah Ebrahim
Nov 11, 2008·The New England Journal of Medicine·Paul M RidkerUNKNOWN JUPITER Study Group
Dec 9, 2008·Nature Genetics·Sekar KathiresanL Adrienne Cupples
Feb 5, 2010·Clinical Pharmacology and Therapeutics·J A DiMasiA Wilson
Mar 10, 2010·Trends in Cardiovascular Medicine·Amit V Khera, Daniel J Rader
Nov 16, 2010·The New England Journal of Medicine·Faiez ZannadUNKNOWN EMPHASIS-HF Study Group
Jan 14, 2011·The New England Journal of Medicine·Amit V KheraDaniel J Rader
Jun 2, 2011·Nature Reviews. Drug Discovery·Fabio PammolliMassimo Riccaboni
Feb 22, 2012·Current Vascular Pharmacology·Tomáš Vaisar
Mar 17, 2012·Lancet·UNKNOWN IL6R Genetics Consortium Emerging Risk Factors CollaborationJohn Danesh
Jun 20, 2012·Statistics in Medicine·Thomas R Fleming, John H Powers
Aug 9, 2012·BMJ : British Medical Journal·Donald W Light, Joel R Lexchin
Nov 1, 2012·European Heart Journal·Seamus C HarrisonSteve E Humphries
Aug 2, 2013·Nature Reviews. Drug Discovery·John Arrowsmith, Philip Miller
Jan 7, 2014·Nature·Yukinori OkadaRobert M Plenge
Jan 23, 2014·JAMA : the Journal of the American Medical Association·Leonard V SacksRachel E Sherman
Apr 10, 2014·Clinical Pharmacology and Therapeutics·S Tuteja, D J Rader
Jul 30, 2014·Human Molecular Genetics·George Davey Smith, Gibran Hemani
Aug 26, 2014·European Heart Journal·Catherine GebhardJean-Claude Tardif
Sep 2, 2014·The New England Journal of Medicine·John J V McMurrayUNKNOWN PARADIGM-HF Investigators and Committees
Dec 18, 2014·Journal of Medical Genetics·Lauren E MokryJ Brent Richards
Dec 19, 2014·Circulation·Dariush MozaffarianUNKNOWN American Heart Association Statistics Committee and Stroke Statistics Subcommittee
Jan 15, 2015·Circulation. Cardiovascular Genetics·Jean-Claude TardifMarie-Pierre Dubé
Apr 18, 2015·Journal of the American College of Cardiology·Christopher B FordyceRobert M Califf
May 15, 2015·European Heart Journal·Yuichi J Shimada, Christopher P Cannon
Jun 8, 2015·International Journal of Epidemiology·Jack BowdenStephen Burgess
Jun 30, 2015·Nature Genetics·Matthew R NelsonPhilippe Sanseau

❮ Previous
Next ❯

Citations

May 14, 2020·Life·Harikrishna Reddy RallabandiYoung Jun Kim
Nov 3, 2016·Current Opinion in Lipidology·Marie-Jeanne BertrandJean-Claude Tardif

❮ Previous
Next ❯

Related Concepts

Related Feeds

Biomarkers for Cardiovascular Risk Assessment

Sensitive and accurate biomarkers used in cardiovascular risk prediction can potentially be used to manage the risk of cardiovascular disease. Discover the latest research on Biomarkers for Cardiovascular Risk Assessment here. Discover the latest research on Biomarkers for Cardiovascular Risk Assessment here.